Know Labs Continues Trading as "KNWN" on the OTC Market
SEATTLE, February 05, 2025--(BUSINESS WIRE)--Know Labs, Inc. (previously NYSE American: KNW, now OTC Markets: KNWN), a pioneering leader in the development and application of radio frequency dielectric spectroscopy (RFDS), announced today it has filed an appeal of the NYSE American’s commencement of proceedings to delist Know Labs from its exchange. The Company will continue working on certain curative actions to regain compliance to maintain its listing while it awaits its appeal to the Listings Qualifications Panel of the Exchange. The Company’s stock will be suspended from trading on the NYSE American during this time. NYSE Regulation is commencing delisting proceedings in connection with its determination, announced today, that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the bid price falling under $.10.
In the interim, effective January 29, 2025, FINRA’s Department of Market Operations has assigned the symbol "KNWN" for quotation and trading of the Company’s stock in the over-the-counter market (OTC Markets).
Know Labs’s CEO, Ron Erickson, stated, "It is unfortunate that Know Labs is having to contend with this at a time when it has just initiated a licensing program of its platform technology, continued to receive peer reviewed recognition of our work, successfully reduced overhead, and continued to advance our proprietary technology. We continue to believe the Company has a bright future and the actions of NYSE will in no way deter our commitment to advance the Company’s business plan and increase shareholder value. We remain steadfast in our goal to deliver non-invasive diagnostics to the marketplace with a first focus on blood glucose monitoring. With the recent announcement of Know Labs Technology Licensing (KTL) we look forward to near term opportunities for licensing our platform technology and revenue generation. As we work through the appeal process with the NYSE, we want to thank our shareholders and stakeholders for their support."
About Know Labs, Inc.
Know Labs, Inc.’s platform technology uses radio frequency spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to be able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. Among the Company’s first expected applications of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration (FDA) clearance prior to its introduction to the market. Other products developed through KTL may not require such prior FDA approval.